Michio Sawada

774 total citations
37 papers, 577 citations indexed

About

Michio Sawada is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Michio Sawada has authored 37 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pathology and Forensic Medicine, 17 papers in Oncology and 11 papers in Immunology. Recurrent topics in Michio Sawada's work include Lymphoma Diagnosis and Treatment (26 papers), CNS Lymphoma Diagnosis and Treatment (9 papers) and Viral-associated cancers and disorders (8 papers). Michio Sawada is often cited by papers focused on Lymphoma Diagnosis and Treatment (26 papers), CNS Lymphoma Diagnosis and Treatment (9 papers) and Viral-associated cancers and disorders (8 papers). Michio Sawada collaborates with scholars based in Japan. Michio Sawada's co-authors include Hisashi Tsurumi, Toshiki Yamada, Senji Kasahara, Hisataka Moriwaki, Tsuyoshi Takami, Nobuhiro Kanemura, Takeshi Hara, Naoe Goto, Takeshi Takahashi and Kenji Fukuno and has published in prestigious journals such as Blood, Scientific Reports and International Journal of Cancer.

In The Last Decade

Michio Sawada

35 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michio Sawada Japan	15	302	207	152	99	91	37	577
Filiz Şen United States	16	278 0.9×	213 1.0×	124 0.8×	112 1.1×	163 1.8×	42	623
Bénédicte Deau France	12	190 0.6×	169 0.8×	118 0.8×	72 0.7×	100 1.1×	43	476
Laura Bellio Italy	10	102 0.3×	186 0.9×	142 0.9×	66 0.7×	82 0.9×	15	508
Jordi Juncà Spain	13	177 0.6×	192 0.9×	194 1.3×	105 1.1×	205 2.3×	83	742
Giovanna Motta Italy	15	206 0.7×	225 1.1×	187 1.2×	132 1.3×	86 0.9×	45	621
Christina Dickson United States	10	90 0.3×	236 1.1×	221 1.5×	46 0.5×	177 1.9×	13	931
Hassan El‐Solh Saudi Arabia	15	164 0.5×	226 1.1×	86 0.6×	261 2.6×	97 1.1×	40	693
Stefano Volpetti Italy	12	220 0.7×	67 0.3×	78 0.5×	45 0.5×	187 2.1×	26	538
Emma Vernon United States	5	74 0.2×	103 0.5×	176 1.2×	63 0.6×	105 1.2×	9	738
J. H. Bourhis France	12	59 0.2×	117 0.6×	74 0.5×	148 1.5×	49 0.5×	35	507

Countries citing papers authored by Michio Sawada

Since Specialization

Citations

This map shows the geographic impact of Michio Sawada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michio Sawada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michio Sawada more than expected).

Fields of papers citing papers by Michio Sawada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michio Sawada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michio Sawada. The network helps show where Michio Sawada may publish in the future.

Co-authorship network of co-authors of Michio Sawada

This figure shows the co-authorship network connecting the top 25 collaborators of Michio Sawada. A scholar is included among the top collaborators of Michio Sawada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michio Sawada. Michio Sawada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nakamura, Nobuhiko, Nobuhiro Kanemura, Takuro Matsumoto, et al.. (2023). Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population. Scientific Reports. 13(1). 19060–19060. 2 indexed citations

Nakamura, Nobuhiko, Junichi Kitagawa, Takao Miwa, et al.. (2023). A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non‐Hodgkin lymphoma. Hematological Oncology. 42(1). e3236–e3236. 1 indexed citations

Goto, Naoe, Hisashi Tsurumi, Senji Kasahara, et al.. (2011). Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. European Journal Of Haematology. 87(3). 217–227. 23 indexed citations

Kasahara, Senji, Takeshi Hara, Hisashi Tsurumi, et al.. (2011). Phase II study of the tetrahydropyranyl adriamycin–cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. Leukemia & lymphoma. 52(4). 629–634. 22 indexed citations

Tsurumi, Hisashi, Takeshi Hara, Naoe Goto, et al.. (2011). A phase II study of rituximab combined with pirarubicin–cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma. Leukemia & lymphoma. 53(2). 247–253. 2 indexed citations

Hara, Takeshi, Hisashi Tsurumi, Naoe Goto, et al.. (2009). Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP. Journal of Cancer Research and Clinical Oncology. 135(10). 1421–1428. 12 indexed citations

Hara, Takeshi, Hisashi Tsurumi, Naoe Goto, et al.. (2009). Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. Journal of Cancer Research and Clinical Oncology. 136(1). 65–70. 17 indexed citations

Hara, Takeshi, Hisashi Tsurumi, Naoe Goto, et al.. (2008). Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). Journal of Cancer Research and Clinical Oncology. 135(1). 53–59. 25 indexed citations

Kanemura, Nobuhiro, Hisashi Tsurumi, Senji Kasahara, et al.. (2007). Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony‐stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy. Hematological Oncology. 26(1). 33–38. 7 indexed citations

10.

Tsurumi, Hisashi, Nobuhiro Kanemura, Takeshi Hara, et al.. (2007). Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide. Journal of Cancer Research and Clinical Oncology. 133(8). 547–553. 10 indexed citations

11.

Kojima, Yasushi, Hisashi Tsurumi, Naoe Goto, et al.. (2006). Fas and Fas ligand expression on germinal center type‐diffuse large B‐cell lymphoma is associated with the clinical outcome. European Journal Of Haematology. 76(6). 465–472. 25 indexed citations

12.

Goto, Naoe, Hisashi Tsurumi, Masao Takemura, et al.. (2006). Serum‐soluble tumor necrosis factor receptor 2 (sTNF‐R2) level determines clinical outcome in patients with aggressive non‐Hodgkin's lymphoma. European Journal Of Haematology. 77(3). 217–225. 29 indexed citations

13.

Tsurumi, Hisashi, Toshiki Yamada, Michio Sawada, et al.. (2004). Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin?s lymphoma. Journal of Cancer Research and Clinical Oncology. 130(2). 107–113. 38 indexed citations

14.

Yamada, Toshiki, Hisashi Tsurumi, Senji Kasahara, et al.. (2003). Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A. Journal of Cancer Research and Clinical Oncology. 129(8). 485–491. 14 indexed citations

15.

Kasahara, Senji, Takeshi Hara, Hiroyasu Itoh, et al.. (2002). Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anaemia by bone marrow stem cell expression of the tumour necrosis factor receptor. British Journal of Haematology. 118(1). 181–188. 15 indexed citations

16.

Sawada, Michio, Hisashi Tsurumi, Toshiki Yamada, et al.. (2002). A prospective study of P‐IMVP‐16/CBDCA: a novel salvage chemotherapy for patients with aggressive non‐Hodgkin's lymphoma who had previously received CHOP therapy as first‐line chemotherapy. European Journal Of Haematology. 68(6). 354–361. 28 indexed citations

17.

Hara, Takeshi, Hisashi Tsurumi, Toshiki Yamada, Michio Sawada, & Hisataka Moriwaki. (2000). Detection of Acute Promyelocytic Leukemia (APL) Cells Intermediately Differentiated by All-Trans Retinoic Acid in the Cerebrospinal Fluid: Central Nervous System Involvement in APL. Leukemia & lymphoma. 39(1-2). 213–215. 3 indexed citations

18.

Hara, Takeshi, Hisashi Tsurumi, Masao Takemura, et al.. (2000). Serum-soluble Fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. American Journal of Hematology. 64(4). 257–261. 39 indexed citations

19.

Matsuda, Yukihiko, et al.. (1987). A case of obstructive jaundice caused by dilated intramural gland of the common bile duct.. Kanzo. 28(12). 1656–1661.

20.

Izukura, Masaaki, Kazuyasu Nakao, Masahiko Miyata, et al.. (1984). A case of mesenteric hematoma of transverse colon.. The Japanese Journal of Gastroenterological Surgery. 17(10). 1904–1907. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact